{
    "clinical_study": {
        "@rank": "164965", 
        "arm_group": {
            "arm_group_label": "Caffeine Dosing", 
            "arm_group_type": "Other", 
            "description": "Single dose of caffeine 100 mg administered"
        }, 
        "brief_summary": {
            "textblock": "This study is designed to determine the pharmacokinetic (PK) profile of a single oral dose\n      of caffeine and the effects that PBT2 has on the metabolism of caffeine in healthy\n      volunteers."
        }, 
        "brief_title": "Phase 1 Study to Determine the Effects of PBT2 on the Pharmacokinetic Profile of Caffeine", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Volunteers", 
        "detailed_description": {
            "textblock": "This study will be conducted in 2 dosing periods with all participants receiving a dose of\n      caffeine 100 mg in Period 1 followed by a 7 day washout period before receiving a further\n      single dose of caffeine 100 mg after 5 consecutive days of receiving PBT2 250 mg .\n      Pharmacokinetic samples will be collected during each dosing period, along with safety\n      monitoring assessments."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy males or females with a BMI between 19 and 30kg/m2\n\n          -  No clinically significant abnormalities\n\n        Exclusion Criteria:\n\n          -  Exposure to medications/drugs that interfere with metabolism of PBT2 including drugs\n             that inhibit or induce CYP1A2\n\n          -  Use of caffeine-containing beverages, supplements or alcohol\n\n          -  Significant history of depression or other psychiatric illness\n\n          -  Surgical or medical conditions which could significantly alter drug absorption,\n             distribution, metabolism or excretion\n\n          -  Unable to swallow capsules or tablets"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02109497", 
            "org_study_id": "PBT2-104"
        }, 
        "intervention": {
            "arm_group_label": "Caffeine Dosing", 
            "description": "PBT2 250 mg administered", 
            "intervention_name": "PBT2", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Caffeine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 7, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Melbourne", 
                    "country": "Australia", 
                    "state": "Victoria", 
                    "zip": "3004"
                }, 
                "name": "Centre for Clinical Studies - Nucleus Network"
            }, 
            "investigator": {
                "last_name": "Jason Lickliter, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Australia"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1, Single Centre, Open Label, Two-period Study in Healthy Volunteers to Determine the Effect of PBT2 on the Pharmacokinetics of Caffeine", 
        "overall_contact": {
            "email": "s.mason@nucleusnetwork.com.au", 
            "last_name": "Sue Mason", 
            "phone": "+61 3 9076 8900"
        }, 
        "overall_official": {
            "affiliation": "Prana Biotechnology", 
            "last_name": "Caroline Herd", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Australia: Department of Health and Ageing Therapeutic Goods Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Area under the plasma concentration versus time curve (AUC) of caffeine after a dose of PBT2 250mg", 
            "safety_issue": "No", 
            "time_frame": "prior to dose on Day 1 and 12 and then 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, 24, 30, 36, 48 hours post each dose."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02109497"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Number of participants with serious and non-serious adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 19 days after first dose of caffeine"
        }, 
        "source": "Prana Biotechnology Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Prana Biotechnology Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}